高血压合并冠心病患者应用瑞舒伐他汀联合氨氯地平的临床效果观察及对其预后质量的影响

Clinical Effect and Influence of the Rosuvastatin Combined with Amlodipine on Prognosis Quality for Patients with Hypertension Combining Coronary Heart Disease

探讨高血压合并冠心病患者应用瑞舒伐他汀联合氨氯地平的临床效果及对其预后质量的影响。纳入2016年9月至2017年9月期间在该院住院治疗的100例高血压合并冠心病患者作为研究对象,按照随机数字表法分为两组,其中对照组50例,采用氨氯地平治疗;观察组50例,采用瑞舒伐他汀联合氨氯地平治疗,比较两组临床疗效及预后主要不良心血管事件(MACE)发生情况。治疗前,两组患者收缩压(SBP)、舒张压(DBP)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平比较,差异不显著(P>0.05);治疗后,两组患者SBP、DBP水平均有所下降,且观察组患者SBP、DBP水平改善程度优于对照组(P<0.05);两组患者TC、TG、LDL-C水平也明显下降,而HDL-C水平明显升高(P<0.05);且观察组患者TC、TG、LDL-C、HDL-C水平改善程度优于对照组,(P<0.05)。随访24个月,治疗组患者主要不良心血管事件(MACE)的发生率为28.0%,明显低于对照组的40.0%,组间比较差异显著(P<0.05)。瑞舒伐他汀联合氨氯地平治疗高血压合并冠心病患者,其降压、降脂作用达到预期效果,有效提高患者预后。

To study the clinical effect and the influence of the rosuvastatin combined with amlodipine on prognosis quality for patients with hypertension combining coronary heart disease,a total of 100 hypertensive patients with coronary heart disease admitted to our hospital from September 2016 to September 2017 were selected as study subjects and divided into two groups by the random number table method. Among them,50 patients in the control group were treated with amlodipine. The treatment group and the observation group were treated with rosuvastatin combined with amlodipine. The clinical efficacy and prognosis of major adverse cardiovascular events（MACE） were compared between the two groups. Before the treatment,there was no significant difference（P〉0. 05） for two groups of patients by comparing the systolic blood pressure,diastolic blood pressure,total cholesterol,triglyceride,low density lipoprotein cholesterol,and high density lipoprotein cholesterol. After the treatment,the SBP and DBP levels of both groups have been decreased to some extent. Moreover,the improvement degree of SBP and DBP in the observation group was better than that in the control group（P〈0. 05）. The levels of TC,TG and LDL-C in two groups have also been decreased significantly,while HDL-C level has been increased significantly（P〈0. 05）. The improvement of TC,TG,LDL-C and HDL-C in the observation group was better than that in the control group（P〈0. 05）. With 24-month follow-up,the incidence of major adverse cardiac event for patients in the treatment group was 28. 0%,which was significantly lower than 40. 0% in the control group,and there was significant difference between the two groups（P〈0. 05）. Treating patients with hypertension combining coronary heart disease by combining rishuvastatin with amlodipine can achieve the anticipated antihypertensive and antilipemic effect,thus effectively improving the prognosis of patients.